Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00623
|
|||||
| Drug Name |
Mefloquine
|
|||||
| Synonyms |
(+)-(11R,2'S)-erythro-Mefloquine; (+)-Mefloquine; (+)-Threo-Mefloquine; (-)-(11S,2'R)-erythro-Mefloquine; (-)-Mefloquine; (-)-Threo-Mefloquine; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol; Alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; Lariam; Lariam (Hydrochloride); Lariam (TN); Mefaquin (TN); Mefloquin; Mefloquina; Mefloquina [INN-Spanish]; Mefloquine (USAN/INN); Mefloquine [USAN:INN:BAN]; Mefloquinone; Mefloquinum; Mefloquinum [INN-Latin]; Mephloquine; RO 13-7224; RO 13-7225; RTI1169-1-1; RTI1172-1-1; RTI1173-1-1; RTI1174-1-1; RTI1188-1-1; RTI1189-1-1; Racemic mefloquine; Ro 21-5998; Ro 21-5998 (Hydrochloride); Ro 215998; Ro-21-5998-001; SPB-80406; WR 142490; WR-142,490; WR-142490; WR-177,602; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Malaria [ICD11:1F40] | Approved | [1] | |||
| Therapeutic Class |
Antimalarials
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C17H16F6N2O
|
|||||
| Canonical SMILES |
C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
|
|||||
| InChI |
InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2/t12-,15+/m1/s1
|
|||||
| InChIKey |
XEEQGYMUWCZPDN-DOMZBBRYSA-N
|
|||||
| CAS Number |
CAS 53230-10-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 378.31 | Topological Polar Surface Area | 45.2 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103446060
,104040016
,104335053
,124892361
,135004437
,135240375
,135611150
,135727482
,137236385
,140239432
,14877790
,175269604
,178101069
,179116766
,223533437
,223712526
,226410988
,243866056
,252401319
,252655885
,26755467
,29216385
,34706437
,47206659
,49681220
,50042965
,50071333
,51051233
,53788688
,56310966
,56313823
,57312460
,603007
,8176741
,85154870
,93166754
,93167184
,9835
|
|||||
| ChEBI ID |
CHEBI:63684
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Doxycycline was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.